Role of Suppression of Endometriosis With Progestins Before IVF-ET

• Status: Completed
• Trial end date: 2020-04-30
• Target enrollment: 0
• Participant gender: Female

Summary

This study aimed to assess the role of Dienogest pretreatment for endometriosis suppression as compared to Gonadotropin-releasing hormone agonist (GnRHa) in patients with endometriosis pursuing IVF treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Research Center, Egypt; National Research Centre, Egypt
• Treatments: Dienogest; Leuprolide

Criteria

Inclusion Criteria:

• confirmed diagnosis of endometriosis

• body mass index < 35 Kg/m2

Exclusion Criteria:

• if they have been already on long-term down-regulation of the pituitary gland with GnRHa for control of endometriosis

• liver or kidney disease

• evidence of diminished ovarian reserve (e.g. high FSH level >12 IU/L or low AMH level <1 ng/ml).